NCT03486873 2026-03-16
MK-3475-587
Merck Sharp & Dohme LLC
Phase 3 Recruiting
Clinical Trials
55 trialsNCT07023289 2026-03-13
A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease
AbbVie
Phase 2 Recruiting
NCT07155187 2026-03-11
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
AbbVie
Phase 2/3 Recruiting
NCT05316701 2026-03-04
Orca-T
Orca Biosystems, Inc.
Phase 3 Active not recruiting
NCT07206056 2026-03-02
TulmiSTAR-01
Novartis
Phase 1/2 Recruiting
NCT06585410 2026-02-25
Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma
Regeneron Pharmaceuticals
Phase 3 Recruiting
NCT06855277 2026-02-24
AcTFirst
Novartis
Phase 3 Recruiting
NCT04876651 2026-02-20
The Present Study Aims to Compare Patients Who Receive the Investigational Product (177Lu-DOTA-rosopatamab) Plus Standard of Care, in Comparison to Standard of Care Only
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 3 Terminated
NCT04485949 2026-02-10
A Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With Glioblastoma
Imvax
Phase 2 Active not recruiting
NCT07005102 2026-01-23
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
AbbVie
Phase 2/3 Recruiting
NCT03602859 2025-12-31
FIRST
Tesaro, Inc.
Phase 3 Active not recruiting
NCT04567420 2025-10-16
DARE
Criterium, Inc.
Phase 2 Recruiting
NCT03778931 2025-09-15
EMERALD
Stemline Therapeutics, Inc.
Phase 3 Completed
NCT04467593 2025-08-05
MATTERS
ElmediX
Phase NA Completed
NCT01711671 2025-08-03
A Study of DKN-01 and Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Leap Therapeutics, Inc.
Phase 1 Completed
NCT03575351 2025-08-03
TRANSFORM
Celgene
Phase 3 Completed
NCT03194646 2025-07-28
ASTEROID 6
Bayer
Phase 3 Terminated
NCT05801965 2025-05-25
A Digital Therapeutic Solution for Cancer Patients
Sidekick Health
Phase NA Completed
NCT06989450 2025-05-25
Digital Patient Support Program for Self-efficacy and Medication Adherence in Women on Adjuvant Endocrine Treatment for Breast Cancer
Sidekick Health
Phase NA Recruiting
NCT06961188 2025-05-07
Clinical Study on Nanocrystalline Megestrol Acetate for Appetite Improvement and Weight Gain in Pre-Cachexia and Cachexia Stages Key Terminology Analysis
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 3 Not yet recruiting
NCT06636682 2024-10-21
FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer
Cellvax Therapeutics Inc
Phase 2 Recruiting
NCT04982627 2024-07-03
BNICHAT
Center for Progressive Recovery, LLC
Phase NA Completed
NCT04099888 2023-09-11
RELEASE
PCI Biotech AS
Phase 2 Terminated
NCT00556374 2023-07-27
Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy
Amgen
Phase 3 Completed
NCT01468623 2023-07-19
PROFUSE
Myriad Genetic Laboratories, Inc.
Phase 4 Terminated
NCT04733833 2023-02-01
A Study to Evaluate the Efficacy and Safety of VB-201 in Patients With COVID-19
Vascular Biogenics Ltd. operating as VBL Therapeutics
Phase 2 Completed
NCT04963972 2022-05-10
Digital and Behavioral Tele-Health Tapering Program for Lowering Dependence on Opioids in Patients Undergoing Surgery
Lucid Lane, Inc
Phase NA Unknown
NCT02107937 2022-05-04
Phase II Study DCVAC/OvCa Added to First Line Carboplatin and Paclitaxel Newly Diagnosed Epithelial Ovarian Carcinoma
Sotio Biotech Inc.
Phase 2 Completed
NCT03329690 2022-03-18
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Gastric Cancer [DESTINY-Gastric01]
Daiichi Sankyo
Phase 2 Completed
NCT04446429 2021-12-10
Anti-Androgen Treatment for COVID-19
Applied Biology, Inc.
Phase NA Completed
NCT04572776 2021-11-09
Phase 3 Study to Assess Resiniferatoxin vs Standard of Care for the Treatment of Intractable Cancer Pain
Sorrento Therapeutics, Inc.
Phase 3 Withdrawn
NCT03393000 2021-07-22
INTACT
Diffusion Pharmaceuticals Inc
Phase 3 Terminated
NCT02448810 2021-05-25
Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
Takeda
Phase 2 Terminated
NCT03301597 2021-03-30
LAUNCH
Nohla Therapeutics, Inc.
Phase 2 Terminated
NCT01883362 2021-03-17
RADIUS
Novartis
Phase 2 Completed
NCT02039726 2021-02-24
(QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive
Daiichi Sankyo
Phase 3 Completed
NCT02369874 2021-02-10
EAGLE
AstraZeneca
Phase 3 Completed
NCT03255980 2020-12-16
Monocenter, Open Label Clinical Investigation on the Treatment of Radiation Induced Dermatitis With Xonrid®
Helsinn Healthcare SA
Phase NA Completed
NCT03323021 2020-11-13
Use of Human Dehydrated Amnion/Chorion (DHACM) Allograft in Partial Nephrectomy
MiMedx Group, Inc.
Phase NA Completed
NCT03472053 2020-05-19
A Study of BIO-11006 in the Treatment of Advanced Non-Small Cell Lung Cancer
BioMarck Pharmaceuticals, Ltd.
Phase 2 Completed
NCT03831633 2019-02-06
Comparative Effectiveness of AKYNZEO® and Standard of Care (Including EMEND®) for the Prevention of Nausea and Vomiting (CINV) in Cancer Patients
VIFORFRANCE
Phase 4 Unknown
NCT02200081 2018-11-15
IMPULSE
Mologen AG
Phase 2 Completed
NCT02107950 2018-08-15
Phase II Study DCVAC/OvCa Plus Carboplatin Gemcitabine Relapsed Platinum (Pt)-Sensitive Epithelial Ovarian Carcinoma
Sotio Biotech Inc.
Phase 2 Completed
NCT02034799 2018-02-26
Phase IV Bioseal Study in Brain Tumor Surgery
Ethicon, Inc.
Phase 4 Completed
NCT03202446 2018-02-23
Randomized Clinical Trial Evaluating the Use of the Laser-Assisted Immunotherapy (LIT/inCVAX) in Advanced Breast Cancer
Eske Corporation S.A.C
Phase 3 Terminated
NCT01310803 2017-10-05
Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder
Endo Pharmaceuticals
Phase 3 Terminated
NCT01353222 2017-05-25
DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
Dendreon
Phase 2 Terminated
NCT02107378 2016-11-30
Efficacy of DCVAC/OvCa Plus Standard of Care in Relapsed Platinum Resistant Epithelial Ovarian Carcinoma
Sotio Biotech Inc.
Phase 2 Terminated
NCT00412217 2016-11-25
A Study of Erlotinib (Tarceva) in Participants With Resected Head and Neck Squamous Cell Cancer
Hoffmann-La Roche
Phase 3 Terminated
NCT00977379 2016-11-15
XERAD
Hoffmann-La Roche
Phase 2 Terminated